TEL AVIV (MarketWatch) -- Teva Pharmaceutical Industries Ltd., the Israeli drugmaker, is in talks to buy Barr Pharmaceuticals Inc. for as much as $7.5 billion, according to published reports. That figure would be a nearly 50% premium for the Montvale, N.J., producer of generic and proprietary pharmaceuticals.
